OpenAI launches GPT-Rosalind, a frontier model purpose-built for life sciences and drug discovery at enterprise scale
GPT-Rosalind and the End of the Vertical AI Excuse For the past two years, the pitch from every life sciences AI startup has followed the same script. General models don’t understand protein folding, reaction mechanisms, or clinical trial design well enough to be useful in production. You need a domain-specific model trained on proprietary biomedical…
